ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1221

Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM)

Albert Chow1, Sean Koester2, Evan Pepper-Tunick3, Peggy Lee4, Mary Eckert5, Laurie Brenchley6, Pamela Gardner6, Naisi Li2, adam Schiffenbauer7, Rita Volochayev7, Nastaran Bayat8, Jeffrey McLean9, Lisa Rider10, Susan Shenoi11, Anne Stevens12 and Neelendu Dey13, 1Loma Linda University, Loma Linda, CA, 2Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, 3Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, 4Department of Oral Medicine, School of Dentistry, University of Washington, Seattle, WA, 5Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA, 6Office of the Clinical Director, NIDCR, National Institutes of Health, Bethesda, MD, 7Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 8Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, 9Department of Periodontics, University of Washington, Seattle, WA, 10NIEHS, NIH, Bethesda, MD, 11Seattle Childrens Hospital, Mercer Island, WA, 12Janssen, Hansville, WA, 13Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, dermatomyositis, microbiome, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: JDM is a rare immune-mediated disease of childhood that is thought to result from genetic predisposition and environmental drivers, with documented links to microbial exposures. In this multi-center, prospective, observational cohort study, we evaluated whether JDM is associated with discrete oral and gut microbiome signatures using siblings to control for family-associated microbial communities.

Methods: We generated 16S rRNA sequence data from fecal, saliva, supragingival, and subgingival plaque samples from JDM probands (n=28, age range 3-18 years, mean age 10 years, 46% female). To control for genetic and environmental determinants of microbiome community structure, we also profiled microbiomes of their unaffected family members (n=27 siblings, n=26 mothers, and n=17 fathers). We performed paired within-family comparisons as well as unpaired analyses of different cohorts.

Results: Family unit was the predominant factor explaining variance in both weighted and unweighted UniFrac distances between samples for each sample type (p< 0.001 in fecal, saliva, supragingival swab, and posterior subgingival dental plaque samples; p< 0.01 in anterior subgingival dental plaque samples, permutational multivariate analysis of variance. Unweighted UniFrac distances between siblings was significantly smaller than the distances between JDM probands in our cohort (p< 0.002, two-tailed Student’s t-test).

In fecal samples, 4% of bacterial amplicon sequence variants (ASVs) were differentially abundant in microbiomes between JDM probands and their siblings (Figure 1A, Table 1). In the case where ASVs that were initially classified as unannotated bacteria during the analyses, taxonomy was assigned based on BLAST results.Approximately 8% of ASVs identified in the anterior subgingival dental plaque were significantly different between JDM probands and their healthy siblings (Figure 1B). In posterior subgingival dental plaque samples, approximately 7% of identified ASVs were significantly differentially abundant between JDM probands and their siblings (Figure 1C). We also observed differentially abundant ASVs in the saliva and supragingival swab samples from JDM probands, all of which were found in very low abundances, including salivary enrichment of Veillonella and Prevotella shahii and depletion of Prevotellamelaninogenica.

Conclusion: The oral and gut microbiomes of JDM probands were more similar to their own unaffected siblings than they were to the microbiomes of other JDM probands, suggesting family unit has a significant effect on microbiome community structure. Nonetheless, in a sibling-paired analysis, several potentially immunomodulatory bacterial taxa were differentially abundant in the microbiomes of JDM probands, including Faecalibacterium in the gut and Streptococcus in the oral cavity. The loss or gain of specific fecal and oral bacteria may potentially play a role in disease pathogenesis and/or be secondary to immune dysfunction in susceptible individuals.

Supporting image 1

Table 1. Differential 16s rRNA Microbial amplicon sequence variants (ASVs) in children with JDM compared to healthy siblings (Percent ± SEM).

Supporting image 2

Figure 1. Differentially abundant ASVs in (A) fecal microbiomes, (B) anterior subgingival dental plaque samples, (C) and posterior subgingival dental plaque samples of JDM probands compared to unaffected siblings. A post-hoc taxonomy was assigned based on BLAST results to the 4 ASVs designated by an asterisk (*) that were initially classified as unannotated bacteria.


Disclosures: A. Chow: None; S. Koester: None; E. Pepper-Tunick: None; P. Lee: None; M. Eckert: None; L. Brenchley: None; P. Gardner: None; N. Li: None; a. Schiffenbauer: None; R. Volochayev: None; N. Bayat: None; J. McLean: None; L. Rider: AstraZeneca, 5, Bristol-Myers Squibb(BMS), 5, Hope Pharmaceuticals, 5; S. Shenoi: None; A. Stevens: Janssen, 2, 5; N. Dey: None.

To cite this abstract in AMA style:

Chow A, Koester S, Pepper-Tunick E, Lee P, Eckert M, Brenchley L, Gardner P, Li N, Schiffenbauer a, Volochayev R, Bayat N, McLean J, Rider L, Shenoi S, Stevens A, Dey N. Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/familial-clustering-of-dysbiotic-oral-and-fecal-microbiomes-in-juvenile-dermatomyositis-jdm/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/familial-clustering-of-dysbiotic-oral-and-fecal-microbiomes-in-juvenile-dermatomyositis-jdm/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology